Principal Financial Group Inc Viking Therapeutics, Inc. Transaction History

Principal Financial Group Inc

$176 Billion
Q2 2025

A detailed history of Principal Financial Group Inc transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 565,066 shares of VKTX stock, worth $21.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

565,066

Previous 598,135 5.53%

Holding current value

$21.4 Million

Previous $14.4 Million 3.67%

% of portfolio

0.01%

Previous 0.01%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$19.98 - $29.49 $660,718 - $975,204	-33,069 Reduced 5.53%	565,066 $15 Million
Q1 2025 Apr 28, 2025	SELL	$24.15 - $42.89 $739,690 - $1.31 Million	-30,629 Reduced 4.87%	598,135 $14.4 Million
Q4 2024 Jan 31, 2025	BUY	$38.28 - $78.03 $24.1 Million - $49.1 Million	628,764 New	628,764 $25.3 Million
Q3 2024 Oct 31, 2024	BUY	$49.84 - $70.47 $6.81 Million - $9.64 Million	136,729 Added 29.93%	593,528 $37.6 Million
Q2 2024 Jul 29, 2024	BUY	$47.39 - $80.2 $4.55 Million - $7.7 Million	95,960 Added 26.59%	456,799 $24.2 Million
Q1 2024 Apr 29, 2024	BUY	$17.4 - $94.5 $6.09 Million - $33 Million	349,725 Added 3146.71%	360,839 $29.6 Million
Q4 2023 Feb 07, 2024	BUY	$9.24 - $19.64 $8,972 - $19,070	971 Added 9.57%	11,114 $206,000
Q3 2023 Nov 02, 2023	SELL	$10.92 - $16.0 $13,191 - $19,328	-1,208 Reduced 10.64%	10,143 $112,000
Q2 2023 Aug 07, 2023	BUY	$14.84 - $24.79 $168,448 - $281,391	11,351 New	11,351 $183,000
Q4 2021 Feb 09, 2022	SELL	$4.6 - $6.72 $67,744 - $98,965	-14,727 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$5.58 - $7.04 $13,319 - $16,804	-2,387 Reduced 13.95%	14,727 $92,000
Q2 2021 Aug 10, 2021	BUY	$5.19 - $6.73 $4,909 - $6,366	946 Added 5.85%	17,114 $102,000
Q1 2021 May 10, 2021	BUY	$5.74 - $9.67 $6,526 - $10,994	1,137 Added 7.56%	16,168 $102,000
Q4 2020 Feb 08, 2021	BUY	$5.3 - $6.71 $1,743 - $2,207	329 Added 2.24%	15,031 $85,000
Q3 2020 Nov 06, 2020	SELL	$5.73 - $8.11 $4,171 - $5,904	-728 Reduced 4.72%	14,702 $85,000
Q2 2020 Aug 05, 2020	BUY	$4.35 - $8.08 $21,267 - $39,503	4,889 Added 46.38%	15,430 $111,000
Q4 2019 Feb 05, 2020	BUY	$6.38 - $8.73 $67,251 - $92,022	10,541 New	10,541 $85,000

Others Institutions Holding VKTX

# of Institutions

451

Shares Held

67.9M

Call Options Held

7.72M

Put Options Held

3.25M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.91B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Viking Therapeutics, Inc. Transaction History